多品牌运作突破专卖瓶颈管理（Multi brand operation breaks through monopoly bottleneck management）.docVIP

多品牌运作突破专卖瓶颈管理（Multi brand operation breaks through monopoly bottleneck management） Trends lead the way, trends guide the industry, and trends explode! Who has grasped the market trend and grasped the trend of customer consumption in time, who will be the boss of the future market? In March 2010, Bright Dairy announced a high-profile collaboration with the global health care product chain, GNC, to march into Chinas health care market. It is the largest vitamin and health food manufacturer in the United States and has more than 6700 stores around the world. Light and GNC combination, illustrates the value of the China huge health care products market and the share of the global 1/5 population of consumer groups, and marked the GNC will fully enter the Chinese health care products industry chain. In April 2010, the domestic health care products marketing model of B2C boss -- Beijing Yisheng health partner in cooperation with the media Reference News published on the nutrition health nutrition national chain to join investment advertising, marking the probiotic health is also fully involved in the store, began to enter the health care industry chain in china. Health care products, a multi-mode coexistence (terminal marketing, conference marketing, direct marketing, etc.), and repeated marketing miracle industry! Today, attracted international and domestic health care products giants have vied for the Chinese health care products chain industry. Disadvantages and challenges of the traditional model The traditional marketing mode of health care products is mainly based on terminal marketing of drugstores. With the influence of national medical reform and the drug price, the sale of terminal pharmacy drug prices by the countrys increasing influence, price transparency, pharmacy profits increasingly thin, and health care products is not affected by the national price ranks, relatively high profits, is the major pharmacies profit growth point. However, with the parity pharma